Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan.
This study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infe...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0273712&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850023518571331584 |
|---|---|
| author | Azumi Ishizaki Xiuqiong Bi Quynh Thi Nguyen Tomomi Maeno Akinori Hara Hiroyuki Nakamura Sanae Kuramoto Koichi Nishi Hiroyasu Ooe Hiroshi Ichimura |
| author_facet | Azumi Ishizaki Xiuqiong Bi Quynh Thi Nguyen Tomomi Maeno Akinori Hara Hiroyuki Nakamura Sanae Kuramoto Koichi Nishi Hiroyasu Ooe Hiroshi Ichimura |
| author_sort | Azumi Ishizaki |
| collection | DOAJ |
| description | This study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infected with SARS-CoV-2 in April 2020 for 12 months (12M). Patients were tested for NAbs and for antibodies against the SARS-CoV-2 nucleocapsid (anti-NC-Ab) and antibodies against the spike receptor-binding domain (anti-RBD-Ab). Tests were performed at 2M, 6M, and 12M after the primary infection (api) with commercially available test kits. In 90.9% (30/33) of patients, NAbs persisted for 12M api, though the median titers significantly declined from 78.7% (interquartile range [IQR]: 73.0-85.0%) at 2M, to 59.8% (IQR: 51.2-77.9) at 6M (P = 0.008), and to 56.2% (IQR: 39.6-74.4) at 12M (P<0.001). An exponential decay model showed that the NAb level reached undetectable concentrations at 35.5 months api (95% confidence interval: 26.5-48.0 months). Additionally, NAb titers were significantly related to anti-RBD-Ab titers (rho = 0.736, P<0.001), but not to anti-NC-Ab titers. In most patients convalescing from COVID-19, NAbs persisted for 12M api. This result suggested that patients need a booster vaccination within one year api, even though NAbs could be detected for over two years api. Anti-RBD-Ab titers could be used as a surrogate marker for predicting residual NAb levels. |
| format | Article |
| id | doaj-art-e70f8568baae47b5bc5267b1143b03e3 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-e70f8568baae47b5bc5267b1143b03e32025-08-20T03:01:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01178e027371210.1371/journal.pone.0273712Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan.Azumi IshizakiXiuqiong BiQuynh Thi NguyenTomomi MaenoAkinori HaraHiroyuki NakamuraSanae KuramotoKoichi NishiHiroyasu OoeHiroshi IchimuraThis study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infected with SARS-CoV-2 in April 2020 for 12 months (12M). Patients were tested for NAbs and for antibodies against the SARS-CoV-2 nucleocapsid (anti-NC-Ab) and antibodies against the spike receptor-binding domain (anti-RBD-Ab). Tests were performed at 2M, 6M, and 12M after the primary infection (api) with commercially available test kits. In 90.9% (30/33) of patients, NAbs persisted for 12M api, though the median titers significantly declined from 78.7% (interquartile range [IQR]: 73.0-85.0%) at 2M, to 59.8% (IQR: 51.2-77.9) at 6M (P = 0.008), and to 56.2% (IQR: 39.6-74.4) at 12M (P<0.001). An exponential decay model showed that the NAb level reached undetectable concentrations at 35.5 months api (95% confidence interval: 26.5-48.0 months). Additionally, NAb titers were significantly related to anti-RBD-Ab titers (rho = 0.736, P<0.001), but not to anti-NC-Ab titers. In most patients convalescing from COVID-19, NAbs persisted for 12M api. This result suggested that patients need a booster vaccination within one year api, even though NAbs could be detected for over two years api. Anti-RBD-Ab titers could be used as a surrogate marker for predicting residual NAb levels.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0273712&type=printable |
| spellingShingle | Azumi Ishizaki Xiuqiong Bi Quynh Thi Nguyen Tomomi Maeno Akinori Hara Hiroyuki Nakamura Sanae Kuramoto Koichi Nishi Hiroyasu Ooe Hiroshi Ichimura Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. PLoS ONE |
| title | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. |
| title_full | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. |
| title_fullStr | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. |
| title_full_unstemmed | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. |
| title_short | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. |
| title_sort | neutralizing antibody response to sars cov 2 for 12 months after the covid 19 workplace outbreaks in japan |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0273712&type=printable |
| work_keys_str_mv | AT azumiishizaki neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT xiuqiongbi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT quynhthinguyen neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT tomomimaeno neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT akinorihara neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT hiroyukinakamura neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT sanaekuramoto neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT koichinishi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT hiroyasuooe neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT hiroshiichimura neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan |